TY - JOUR
T1 - Oxidant Stress Is Increased during Treatment of Human Immunodeficiency Virus Infection
AU - Hulgan, Todd
AU - Morrow, Jason
AU - D'Aquila, Richard T.
AU - Raffanti, Stephen
AU - Morgan, Michael
AU - Rebeiro, Peter
AU - Haas, David W.
N1 - Funding Information:
Financial support: National Institutes of Health (grants T32 AI 07474 and K12 RR 17697 [to T.H.] and R01 DK-048831 [to J.M.]). We also acknowledge the Vanderbilt-Meharry Center for AIDS Research application process (grant P30 AI054999).
PY - 2003/12/15
Y1 - 2003/12/15
N2 - Some diseases and environmental exposures, including those that are risk factors for atherosclerosis, are associated with increased oxidant stress. The objective of this cross-sectional, observational study was to determine whether oxidant stress is increased during human immunodeficiency virus type 1 (HIV-1) infection or its therapy. To quantify oxidant stress, plasma F2 isoprostane (F2-IsoP) concentrations were determined by gas chromatography/mass spectroscopy. A total of 120 subjects were enrolled during routine primary care visits. The median CD4+ T cell count was 341 cells/mm3, the median HIV-1 RNA level was 3.4 log10 copies/ mL, and 74% of patients were receiving antiretroviral therapy. Plasma F2-IsoP concentrations were 12-149 pg/mL (median, 31 pg/mL). In univariate analysis, higher F2-IsoP concentrations were associated with lower log10 plasma HIV-1 RNA levels (P = .009) and with efavirenz use (P = .02). Both factors remained associated with plasma F 2-IsoP concentrations in multivariate analysis. Oxidant stress associated with therapeutic control of viral replication may have important implications for long-term complications of antiretroviral therapy.
AB - Some diseases and environmental exposures, including those that are risk factors for atherosclerosis, are associated with increased oxidant stress. The objective of this cross-sectional, observational study was to determine whether oxidant stress is increased during human immunodeficiency virus type 1 (HIV-1) infection or its therapy. To quantify oxidant stress, plasma F2 isoprostane (F2-IsoP) concentrations were determined by gas chromatography/mass spectroscopy. A total of 120 subjects were enrolled during routine primary care visits. The median CD4+ T cell count was 341 cells/mm3, the median HIV-1 RNA level was 3.4 log10 copies/ mL, and 74% of patients were receiving antiretroviral therapy. Plasma F2-IsoP concentrations were 12-149 pg/mL (median, 31 pg/mL). In univariate analysis, higher F2-IsoP concentrations were associated with lower log10 plasma HIV-1 RNA levels (P = .009) and with efavirenz use (P = .02). Both factors remained associated with plasma F 2-IsoP concentrations in multivariate analysis. Oxidant stress associated with therapeutic control of viral replication may have important implications for long-term complications of antiretroviral therapy.
UR - http://www.scopus.com/inward/record.url?scp=0346848715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346848715&partnerID=8YFLogxK
U2 - 10.1086/379776
DO - 10.1086/379776
M3 - Article
C2 - 14689356
AN - SCOPUS:0346848715
VL - 37
SP - 1711
EP - 1717
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 12
ER -
